Mutations in exons 18–21 of the epidermal growth factor receptor gene (EGFR) can confer
sensitivity to EGFR-tyrosine kinase inhibitors (EGFR-TKIs) in patients with non-small-cell …

Introduction Patients with non-small cell lung cancer (NSCLC) harboring uncommon
epidermal growth factor receptor (EGFR) mutations are a heterogeneous group exhibiting …

Epidermal growth factor receptor (EGFR) mutations are the second most common oncogenic
driver event in non-small cell lung cancer (NSCLC). Classical activating mutations (exon 19 …

Simple Summary The advent of epidermal growth factor receptor (EGFR) tyrosine kinase
inhibitors (EGFR-TKIs) has led to a dramatic improvement in the prognosis of patients …

Background Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs) are
standard of care for patients with EGFR mutation-positive non–small-cell lung cancer …

Non-small-cell lung cancer with epidermal growth factor receptor (EGFR) mutation is
sensitive to EGFR tyrosine kinase inhibitors (TKIs). But little is known about the response to …

Molecular profiling in advanced non-small cell lung cancer (NSCLC) has allowed for the
detection of actionable mutations, which has revolutionized the treatment paradigm in this …

Introduction Epidermal growth factor receptor (EGFR) 19del and L858R mutation are known
as “common mutations” in non-small cell lung cancer (NSCLC) and predict sensitivities to …

Background Molecular characterization of non–small-cell lung cancer (NSCLC), defined
predictive and druggable mutations that greatly modified patient prognoses. The most …

Introduction• Literature review‐Molecular biology of EGFR mutations‐Clinical characteristics
of NSCLC patients with EGFR mutations‐Genetic characteristics of EGFR‐mutated tumours …